Camptothecin induced DDX5 degradation increased the camptothecin resistance of osteosarcoma

Xingkai Zhao1, Miao Bao2, Fengmin Zhang3

  • 1Department of Orthopedic Surgery, the First Affiliated Hospital of Harbin Medical University, Harbin, China.

Insights

Osteosarcoma chemo-resistance is linked to DDX5 protein loss. Restoring DDX5 may improve camptothecin treatment effectiveness in bone cancer patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Osteosarcoma (OS) is a prevalent bone cancer in children and adolescents.
  • Chemo-resistance significantly hinders effective OS treatment.
  • The molecular basis of chemo-resistance in OS is not fully understood.

Purpose of the Study:

  • To investigate the molecular mechanisms underlying chemo-resistance in osteosarcoma.
  • To identify potential therapeutic targets for overcoming camptothecin resistance in OS.

Main Methods:

  • Utilized 143B osteosarcoma cells.
  • Investigated the role of DDX5 protein in camptothecin (cpt) resistance.
  • Examined the interaction between DDX5 and NONO, a DNA repair protein.

Main Results:

  • Camptothecin (cpt) resistance in OS cells was associated with the degradation of DDX5.
  • Knockdown of DDX5 reduced cpt-induced cell death and DNA damage, enhancing cell proliferation.
  • DDX5 regulates the function of the DNA repair protein NONO, and its degradation disrupts this interaction, contributing to cpt resistance.

Conclusions:

  • DDX5 degradation is a key mechanism driving chemo-resistance to camptothecin in osteosarcoma.
  • DDX5 may serve as a potential therapeutic target to enhance camptothecin efficacy in OS treatment.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.5K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.5K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
5.7K